Jefferies Has Decided To Downgrade Armo Biosciences Inc (ARMO) Shares

June 13, 2018 - By Hazel Jackson

Armo Biosciences Inc (ARMO) Receives a Downgrade

Trading for shares of Armo Biosciences Inc (ARMO) will be very interesting to watch, as Jefferies cut the rating for the stock to a Hold. In addition to the ratings downgrade, Jefferies analysts have given the shares a target of $50.0000 which is -0.02 % higher than before.

ARMO BioSciences, Inc. (NASDAQ:ARMO) Ratings Coverage

Among 4 analysts covering ARMO BioSciences (ARMO), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. ARMO BioSciences has $75.0 highest and $5000 lowest target. $63.25’s average target is 26.47% above currents $50.01 stock price. ARMO BioSciences had 7 analyst reports since February 20, 2018 according to SRatingsIntel. The rating was downgraded by BMO Capital Markets to “Hold” on Thursday, May 10. On Tuesday, February 20 the stock rating was initiated by Robert W. Baird with “Buy”. The company was initiated on Tuesday, February 20 by Jefferies. Leerink Swann upgraded the shares of ARMO in report on Tuesday, March 27 to “Buy” rating. On Tuesday, February 20 the stock rating was initiated by BMO Capital Markets with “Buy”.

The stock increased 0.08% or $0.04 during the last trading session, reaching $50.01. About 114,486 shares traded. ARMO BioSciences, Inc. (ARMO) has 0.00% since June 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Analysts await ARMO BioSciences, Inc. (NASDAQ:ARMO) to report earnings on July, 2. After $-9.62 actual EPS reported by ARMO BioSciences, Inc. for the previous quarter, Wall Street now forecasts -95.01 % EPS growth.

ARMO BioSciences, Inc., an immuno-oncology company, develops a pipeline of novel product candidates that activate the immune system of cancer patients to recognize and eradicate tumors in the United States. The company has market cap of $1.52 billion. The Company’s lead product candidate includes AM0010, a drug that is in Phase III randomized pivotal clinical trial for the treatment of pancreatic ductal adenocarcinoma and chemotherapy. It currently has negative earnings. The firm is also developing AM0010 with anti-PD-1 immune checkpoint inhibitor that has completed Phase I/Ib clinical trial for the treatment of non-small cell lung cancer, as well as that is in Phase I/Ib clinical trial for the treatment of renal cell carcinoma, and melanoma and other solid tumors.

More important recent ARMO BioSciences, Inc. (NASDAQ:ARMO) news were published by: which released: “Star Kleiner Perkins VC may be launching her own firm” on May 15, 2018, also published article titled: “Top Analyst Upgrades and Downgrades: Applied Materials, Comcast, HUYA, Sprint, Time Warner, Yelp and More”, published: “Spotlight On Gambling Reset And Banking Bill” on May 19, 2018. More interesting news about ARMO BioSciences, Inc. (NASDAQ:ARMO) was released by: and their article: “The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines” with publication date: June 03, 2018.

ARMO BioSciences, Inc. (NASDAQ:ARMO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: